{"id":"W4386784925","doi":"10.1158/1557-3265.aacrahns23-po-007","title":"Abstract PO-007: A phase 2 open-label study of conditionally active biologic, ozuriftamab vedotin (BA3021) in PD-1/L1 failure patients with recurrent or metastatic squamous cell carcinoma of the head and neck","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Head and neck squamous-cell carcinoma; Cancer; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Head and neck cancer; Cancer research; Clinical trial","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001246905,0.001268496,0.00123578,0.0003224992,0.0003754622,0.001055997,0.0007259,0.001137345,0.00487788],"category_scores_gemma":[0.0005685632,0.0004491418,0.0009492944,0.0002620981,0.0008669903,0.001156695,0.0003007075,0.002701327,0.001227369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009213563,"about_ca_system_score_gemma":0.001397322,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008241067,"about_ca_topic_score_gemma":0.002098763,"domain_scores_codex":[0.9997575,0.0000871559,0.00001283248,0.00005427785,0.00002691385,0.00006127091],"domain_scores_gemma":[0.9996651,0.0000423544,0.0000494828,0.00002837596,0.00003305732,0.0001816276],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6291031,0.1165662,0.004448968,0.001358149,0.001257752,0.0003429423,0.0004533915,0.002474734,0.1024305,0.0008358482,0.007517607,0.1332107],"study_design_scores_gemma":[0.4842242,0.4984373,0.00537906,0.0000380978,0.0002954454,0.000262135,0.00008215818,0.001779194,0.005352405,0.0003432349,0.003774371,0.00003236718],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917163,0.001347286,0.0006713382,0.0004029307,0.0001268102,0.002606613,0.001001048,0.0001342367,0.001993456],"genre_scores_gemma":[0.9881029,0.001077008,0.001651826,0.00071326,0.0001158369,0.002796693,0.001895813,0.00003458199,0.003612167],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00487788,"threshold_uncertainty_score":0.01631808,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3121192668751875,"score_gpt":0.541136698782141,"score_spread":0.2290174319069535,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}